Streetwise Reports' Article Archives — January 2022 back to current month (36)
Co. Focused on Pipeline of Drug Candidates (01/31/2022)
In the clinic, Algernon Pharmaceuticals is advancing Ifenprodil in three indications and DMT in stroke, noted a Research Capital Corp. report.
Shares of Provention Bio Inc. traded 29% higher after the company reported that following its Type B meeting and conversations with the U.S. FDA, it is now planning to resubmit a Biologics License Application for delay of clinical type 1 diabetes in at-risk individuals.
ProMIS Neurosciences appointed to its science advisory board Canada-based Dr. Cheryl Wellington, professor, neuroscientist and head of a globally recognized neuro research program.
During Streetwise Live! on Jan. 27, 2022, representatives of Algernon Pharmaceuticals discussed the use of the psychedelic DMT in stroke sufferers. On the broadcast were Algernon CEO Christopher Moreau and consultants to the firm, Dr. David Nutt and Dr. Rick Strassman.
Co. Meets Goals in COVID Drug Trial (01/28/2022)
Todos Medical has closed a Phase 2 trial of its antiviral 3CL protease inhibitor Tollovir after getting positive interim data.
FDA Approves First Tubeless Insulin Delivery Device (01/28/2022)
Shares of Insulet Corp. traded 15% higher after the company reported its Omnipod® 5 automated insulin delivery system has received clearance from the U.S. FDA. The Omnipod® 5 is the first tubeless system to be monitored and controlled remotely using a smartphone.
Forward Water Technologies Corp. is exploring applications for its forward osmosis water technology in the lithium extraction industry.
Possible Treatment for CRC Shows Promise (01/25/2022)
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report.
Algernon Pharmaceuticals Inc. has included novel salt forms of a psychedelic drug being investigated to combat strokes in its intellectual property applications.
Bone Cancer Drug Meets Goals, Stocks Rise (01/25/2022)
Shares of Sierra Oncology Inc. traded 48% higher after the company reported that topline data obtained during its Pivotal Phase 3 MOMENTUM Myelofibrosis Study showed that its momelotinib produced statistically significant improvements in anemia and splenic size.
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report.
Fourth COVID-19 Vaccine Shot Shown Less Effective (01/24/2022)
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report.
‘Strong Data’ Expected From Todos Medical Data Lock (01/24/2022)
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.
GNC to Distribute Products for CBD Co. (01/22/2022)
The agreement with GNC is a step toward Charlotte's Web Holdings' goals of expanding consumer access to its products and becoming cash flow positive this year, noted a ROTH Capital Partners report.
First NSCLC Patient Dosed With Trial Therapeutic (01/22/2022)
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report.
Fund Triples Holding of Drug Repurposing Firm (01/20/2022)
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.
US Cannabis Firm in 'State of Flux' (01/19/2022)
With several market factors working against Stem Holdings, its future is uncertain, noted a Noble Capital Markets report.
Shares of Zogenix Inc. rose by 66% after the company reported it entered into an agreement to be acquired by UCB. S.A. of Belgium for $26.00 per share in cash. The offer includes the potential for an additional $2.00 per share if a specific drug approval milestone is met.
The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report.
Derm Biopharma Named Top Growth Pick For 2022 (01/18/2022)
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.
This Pharmaceutical Company Has a Brilliant Concept (01/17/2022)
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.
Ph1 Trial Results of Dementia Drug Positive (01/12/2022)
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.
Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report.
Shares of new class synthetic vaccine developer Vaxxinity Inc. traded 23% higher after the company reported it has dosed the first patient in its Phase 1b UB-312 Parkinson's disease study.
Biotech Co. Partners With Life Sciences Firms (01/11/2022)
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.
Accolade Inc. shares rose 27% after the company reported Q3/22 financial results that included a 117% increase in YoY revenue. The firm highlighted that in calendar year 2021, its membership increased four-fold from 2 million to 10 million.
2022 to Be Catalyst Rich for Biopharma (01/10/2022)
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.
Enrollment Done for COVID-19 Drug Trial (01/10/2022)
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.
AI Driven Drug Firm Partners With Merck (01/07/2022)
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.
Co. Partners to Test New Cancer Vaccines (01/06/2022)
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash.
Chen Lin's Top 6 Investment Ideas (01/05/2022)
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.
New Muscular Dystrophy Drug Shows Promise (01/05/2022)
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.
Co. Plans to Make 100M Rapid COVID Tests Monthly (01/05/2022)
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.
Lead Cancer Drug Gets Fast Tracked (01/03/2022)
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|